title: [Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade].
abstract: Evaluation of the prognostic value of prostatic markers with regard to disease progression after endocrine therapy in patients with prostate carcinoma. A total of 51 patients (21 stage C, 5 stage D1 and 25 stage D2). Endocrine therapy consisted in complete hormonal blockade with flutamide and an LH-RH analog depot (leuprolide). PSA-PAP levels were determined both pre-treatment and during follow-up of patients using radioimmunometric techniques. Follow-up extended for 13 to 62 months (mean 30 months). Death due to progression happened in 24 of 51 patients. Previous PSA levels did not correlate to progression. Changes in PSA levels during treatment and time scope when they occurred were associated to subsequent evolution. Patients with PAP higher than 10 ng/ml at the beginning of therapy experienced higher progression rates (p < 0.05). Decrease of PSA levels by a percentage greater than 80% during the first quarter of treatment relative to initial figures was related to lower progression rates (p < 0.01). Maintenance of high levels in the first six months of treatment predicted a higher progression rate (p < 0.001). The study suggests a better prognosis for patients wit decreased serum PSA rates by a percentage of around 80% after one to three months treatment.
authors.affiliation: Servicio de Urología, Hospital Regional Universitario Reina Sofía de Córdoba.
authors.forename: J C
authors.initials: JC
authors.lastname: Regueiro López
authors.forename: F
authors.initials: F
authors.lastname: Ruiz Alvarez Cienfuegos
authors.forename: M
authors.initials: M
authors.lastname: Leva Vallejo
authors.forename: M J
authors.initials: MJ
authors.lastname: Requena Tapia
authors.forename: J A
authors.initials: JA
authors.lastname: Merchan García
authors.forename: R
authors.initials: R
authors.lastname: Prieto Castro
authors.forename: J
authors.initials: J
authors.lastname: Alvarez Kindelan
mesh_terms: D000135:Acid Phosphatase / Q000097:blood*; D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D011379:Prognosis; D011467:Prostate; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D005485:Flutamide; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen; D016729:Leuprolide
vernacular_title: Significado pronóstico de los marcadores prostáticos en pacientes portadores de adenocarcinoma prostático bajo bloqueo hormonal completo.